Agennix AG / Agennix AG Raises EUR 9.8 Million (~$13 Million) in Private Placement with Existing Shareholders processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. 

Martinsried/Munich  (Germany), Princeton,  NJ and  Houston, TX, March 21, 2010 -
Agennix  AG (Frankfurt Stock Exchange: AGX) today announced that the Company has
raised  approximately  EUR  9.8 million  (approximately  $13 million) in a private
placement  with existing shareholders. Agennix  sold 1,870,523 shares at a price
of  EUR 5.22 per share. The newly issued shares, which were issued from authorized
capital,   represent  9.1% of  Agennix's  total  shares  outstanding  after  the
transaction.

The  Management  Board  and  Supervisory  Board  of Agennix approved the capital
increase  at  their  meetings  on  March  21, 2010.  The Company has resolved to
increase  its total share capital from EUR 18,707,432 by an amount of EUR 1,870,523
to  a  total  share  capital  of  EUR 20,577,955 by issuing 1,870,523 new ordinary
bearer  shares. The  pre-emptive rights  of the  existing shareholders have been
excluded.

"This  private placement is the first part of our plan to re-finance the Company
this  year. We are pleased with the enthusiasm expressed by current shareholders
for  our talactoferrin development program,"  said Torsten Hombeck, Ph.D., Chief
Financial  Officer. "The  funds  we  have  raised  will  enable  us  to continue
full-scale  enrollment  in  the  Phase  3 FORTIS-M  trial in non-small cell lung
cancer  and to prepare  for meetings with  regulatory authorities to discuss the
next  steps  following  the  positive  Phase  2 trial of talactoferrin in severe
sepsis."

Agennix  intends to use the  proceeds of this private  placement to continue the
development of talactoferrin and to fund ongoing operations.
About Agennix

Agennix  AG is  a publicly  traded biopharmaceutical  company that is developing
novel  therapies in areas of major unmet  medical need to improve the length and
quality  of life of seriously ill  patients. The Company's most advanced program
is  talactoferrin, an  oral targeted  therapy that  has demonstrated activity in
randomized,  double-blind, placebo-controlled Phase  2 studies in non-small cell
lung  cancer as well as in severe sepsis. Talactoferrin is currently in Phase 3
clinical  trials  in  non-small  cell  lung  cancer.  Other clinical development
programs  include  RGB-286638,  a  multi-targeted  kinase  inhibitor in Phase 1
testing; the oral platinum-based compound satraplatin; and a topical gel form of
talactoferrin  for  diabetic  foot  ulcers.  Agennix's  registered  seat  is  in
Heidelberg,    Germany.    The   Company   has   three   sites   of   operation:
Martinsried/Munich,  Germany;  Princeton,  New  Jersey  and  Houston, Texas. For
additional information, please visit the Agennix Web site at www.agennix.com.

The  shares have not been, and will not be, registered under the U.S. Securities
Act of 1933, as amended, or any state securities laws in the U.S., and unless so
registered,  may not be offered or sold in the United States absent registration
or  an applicable  exemption from  registration requirements.  This announcement
does not constitute an offer to sell or the solicitation of an offer to buy, nor
shall  there be any sale of shares in any state in the U.S. in which such offer,
solicitation  or sale would  be unlawful prior  to registration or qualification
under the securities laws of any such state.

This  press  release  contains  forward-looking  statements,  which  express the
current  beliefs  and  expectations  of  the  management  of  Agennix  AG.  Such
statements  are  based  on  current  expectations  and  are subject to risks and
uncertainties,  many of  which are  beyond our  control, that could cause future
results,  performance or achievements to  differ significantly from the results,
performance  or  achievements  expressed  or  implied  by  such  forward-looking
statements.  There can be no guarantee  that the Company will procure additional
funding  that is  sufficient to  continue its  operations. Actual  results could
differ materially depending on a number of factors, and we caution investors not
to  place undue  reliance on  the forward-looking  statements contained  in this
press  release. Forward-looking  statements speak  only as  of the date on which
they   are   made   and   Agennix  undertakes  no  obligation  to  update  these
forward-looking  statements, even  if new  information becomes  available in the
future.


For further information, please contact:

Agennix
AG
Investor Relations & Corporate Communications
Phone: +49 (0)89
8565 2693
ir@agennix.com


In the U.S.: Laurie
Doyle
Director, Investor Relations & Corporate Communications
Phone: +1 609 524 5884

laurie.doyle@agennix.com


Additional media contacts for Europe:
MC Services
AG
Phone: +49 (0) 89 210 228 0

Raimund
Gabriel
raimund.gabriel@mc-services.eu


Hilda
Juhasz
hilda.juhasz@mc-services.eu



Additional investor contact for Europe:
Trout International
LLC
Lauren Williams, Vice President
Phone: +44 207 936 9325
lwilliams@troutgroup.com







[HUG#1395907]



 --- End of Message --- 

Agennix AG
Fraunhoferstr. 20 Martinsried Germany

ISIN: DE000A1A6XX4;
Listed: Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;